TAH Drug Code | EDUAH |
---|---|
Indications | Bronchial asthma |
Dosing | For adults and children aged 12 and above: Initial dose: 400-1600 mcg/day, divided into 2-4 doses. Maintenance dose: 200-400 mcg/day, divided into 2 doses. For children aged 6-12: Initial dose: 200-400 mcg/day, divided into 2 doses. Maintenance dose: Individualized-the minimum dose needed-keep patients symptom-free. For stable asthma, twice daily usage is usually sufficient. Patients using inhaled bronchodilators should use the bronchodilator a few minutes before using Budesonide to enhance drug penetration into the bronchial branches and reduce local side effects, such as cough. When the dose exceeds 800mcg, the use of a spacer is recommended, as it can reduce systemic absorption and improve drug deposition in the lungs. |
Hepatic Impairment | Dose adjustment not necessary |
Renal Impairment | Dose adjustment not necessary |
Contraindications | Hypersensitivity to budesonide or any component of the formulation. Moderate to severe bronchial dilation. |
Adverse Effects | Common: Hypertension (Oral, 12%), Peripheral edema (Oral, 17%), Acne (Oral, 2.4-11%), Dermatitis (Oral, 6%), Hirsutism (Oral, 5%), Weight gain (Inhalation, 1-3% ; oral, 7%), Diarrhea (Inhalation, 2-4% ; oral, 10%), Indigestion (Oral, 6-7%), Nausea (Inhalation, 1.8% ; oral, 5.1-11%; rectal, 2%), Leukocytosis (Oral, up to 6%), Arthralgia (Oral, 2-6%), Spasm (Oral, 12%), Headache (Inhalation, >3% ; oral, 10-21%), Bleeding from nose (Inhalation, 2-4% ; intranasal, 8%), Dyspnea (Oral, 6%), Nasal stinging/burning (Intranasal, up to 1%), Respiratory tract infection (Inhalation, 3-38% ; oral, 8-11%), Sinusitis (Inhalation, 3% or greater ; oral, 8%), Edema of face (Oral, 8%), Fatigue (Inhalation, 1-<3% ; oral, 3.1-5%) Serious: Syncope (Inhalation, 1-3%), Cushing's syndrome (Oral, 5-15% ; inhalation, rare), Hyperglycemia, Hypocortisolism secondary to another disorder (Inhalation, rare ; oral, 4.3% ; rectal, 4%), Type 2 diabetes mellitus, Anaphylaxis, Hypersensitivity reaction, Fracture of bone (Inhalation, 1-3%), Osteoporosis, Cataract, Glaucoma, Pneumonia, Angioedema |
Pregnancy | Compatible |
Lactation | No (Limited) Human Data - Probably Compatible |
More Info | UpToDate |
TAH Drug Code | EPULR |
---|---|
Indications | Patients with bronchial asthma not well controlled by bronchodilators &/or antiallergic agents. |
Dosing | The required dose can be administered at one time under 1mg, otherwise, divided in 2 times daily when the required dose above 1mg. Adult: Initial dose: 1-2 mg daily. Maintenance dose: 0.5-4mg daily. May increase the dosage with the very severe patient. Child > 6 months: Loading dose: 0.25-0.5mg daily. May up to 1mg daily if required. Maintenance dose: 0.25-2mg daily. |
Hepatic Impairment | Dose adjustment not necessary |
Renal Impairment | Dose adjustment not necessary |
Contraindications | Hypersensitivity to budesonide or any other ingredients. |
Adverse Effects | Common: Hypertension (Oral, 12%), Peripheral edema (Oral, 17%), Acne (Oral, 2.4-11%), Dermatitis (Oral, 6%), Hirsutism (Oral, 5%), Weight gain (Inhalation, 1-3% ; oral, 7%), Diarrhea (Inhalation, 2-4% ; oral, 10%), Indigestion (Oral, 6-7%), Nausea (Inhalation, 1.8% ; oral, 5.1-11%; rectal, 2%), Leukocytosis (Oral, up to 6%), Arthralgia (Oral, 2-6%), Spasm (Oral, 12%), Headache (Inhalation, >3% ; oral, 10-21%), Bleeding from nose (Inhalation, 2-4% ; intranasal, 8%), Dyspnea (Oral, 6%), Nasal stinging/burning (Intranasal, up to 1%), Respiratory tract infection (Inhalation, 3-38% ; oral, 8-11%), Sinusitis (Inhalation, 3% or greater ; oral, 8%), Edema of face (Oral, 8%), Fatigue (Inhalation, 1-<3% ; oral, 3.1-5%) Serious: Syncope (Inhalation, 1-3%), Cushing's syndrome (Oral, 5-15% ; inhalation, rare), Hyperglycemia, Hypocortisolism secondary to another disorder (Inhalation, rare ; oral, 4.3% ; rectal, 4%), Type 2 diabetes mellitus, Anaphylaxis, Hypersensitivity reaction, Fracture of bone (Inhalation, 1-3%), Osteoporosis, Cataract, Glaucoma, Pneumonia, Angioedema |
Pregnancy | Compatible |
Lactation | No (Limited) Human Data - Probably Compatible |
More Info | UpToDate |